VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
EHC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
EHCEncompass Health Corporation
$122.01$12.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. EHC
  4. Financial Ratios

Encompass Health Corporation (EHC) Financial Ratios

Latest Ratios: P/E Ratio 22.0x · EV/EBITDA 10.7x · ROE 18.5%. (1996–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

EHC Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$12.1B$10.8B$9.4B$6.8B$6.0B$5.2B$6.6B$5.5B$4.9B$3.9B$3.3B
Enterprise Value$14.7B$13.5B$12.1B$9.6B$9.0B$8.6B$9.9B$8.7B$7.3B$6.4B$6.2B
P/E Ratio →22.0219.1620.7119.2322.1512.6323.0715.2616.7414.6112.66
P/S Ratio2.041.831.761.411.381.301.841.191.141.000.90
P/B Ratio3.813.313.312.943.232.173.282.832.622.373.06
P/FCF27.5624.7026.2025.2549.3431.5922.1323.689.959.478.10
P/OCF10.309.239.417.948.517.269.318.626.425.945.39

P/E links to full P/E history page with 30-year chart

EHC EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—2.272.252.002.062.152.771.901.721.641.71
EV / EBITDA10.659.7510.374.8010.279.8213.369.588.337.717.59
EV / EBIT13.9712.5113.6013.1014.3312.9018.4112.0911.469.879.54
EV / FCF—30.6433.4935.8173.7552.4433.3337.7514.9215.5915.50

EHC Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin95.7%95.7%41.6%41.3%40.3%42.4%95.2%96.4%96.3%96.2%96.2%
Operating Margin17.7%17.7%16.1%35.9%14.5%16.4%—15.0%15.9%16.6%17.8%
Net Profit Margin9.5%9.5%8.5%7.3%6.2%10.3%8.0%7.8%6.8%6.9%6.8%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE18.5%18.5%17.7%16.9%12.7%18.7%14.4%18.9%16.6%20.0%25.2%
ROA8.3%8.3%7.2%6.0%4.3%6.2%4.5%6.3%5.8%5.7%5.3%
ROIC13.9%13.9%12.2%26.0%8.9%8.9%—10.9%12.0%11.9%12.1%
ROCE17.6%17.6%15.5%32.8%11.3%11.1%—14.0%15.3%15.1%15.5%

EHC Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.830.830.951.281.611.451.771.731.341.572.83
Debt / EBITDA1.971.972.331.473.423.964.793.672.853.093.67
Net Debt / Equity—0.800.921.231.601.431.661.681.311.532.79
Net Debt / EBITDA1.891.892.261.423.403.904.493.572.773.033.62
Debt / FCF—5.947.3010.5724.4120.8511.1914.074.976.127.39
Interest Coverage8.748.746.465.103.574.072.924.524.354.223.80

EHC Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio1.081.081.051.281.251.231.321.050.981.361.38
Quick Ratio1.081.081.051.281.251.231.321.050.901.241.25
Cash Ratio0.170.170.100.220.040.070.310.130.100.110.09
Asset Turnover—0.840.820.790.770.580.550.760.820.800.78
Inventory Turnover————————2.692.392.30
Days Sales Outstanding—38.0840.6846.5045.0645.6557.6239.5339.9144.0344.47

EHC Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield0.6%0.7%0.7%0.9%1.6%2.2%1.7%2.0%2.1%2.3%2.6%
Payout Ratio12.6%12.6%13.8%17.2%36.5%27.2%39.4%30.3%34.5%33.8%33.8%

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield4.5%5.2%4.8%5.2%4.5%7.9%4.3%6.6%6.0%6.8%7.9%
FCF Yield3.6%4.0%3.8%4.0%2.0%3.2%4.5%4.2%10.0%10.6%12.3%
Buyback Yield1.3%1.5%0.3%0.1%0.1%0.3%0.1%0.8%1.3%1.0%2.0%
Total Shareholder Yield1.9%2.1%1.0%1.0%1.8%2.4%1.8%2.8%3.4%3.3%4.6%
Shares Outstanding—$102M$102M$101M$100M$100M$100M$99M$100M$99M$100M

Key Metrics

Growth RegimeAccelerating
ProfitabilityStrong
Balance SheetAdequate
Cash FlowStable
Top Statement Risk

Government payer concentration risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Margin Expansion Despite Labor Pressures

Operating margin expanded from 15.5% in Q3 2024 to 19.0% in Q1 2026, while net margin improved to 12.3%, reflecting operating leverage and cost discipline. According to recent financial statements, gross margin volatility (41-48%) suggests labor cost variability.

The reported gross margin swings between 41% and 48% likely reflect the classification of clinical labor as an operating expense rather than cost of goods sold, a common convention in healthcare services. The steady expansion in operating margin from 15.5% to 19.0% over the past two years indicates that revenue growth is outpacing fixed cost growth, a sign of operating leverage. However, the Q2 2026 net margin of 9.6% dipped from Q1's 12.3%, possibly due to one-time items or tax rate fluctuations, warranting monitoring for sustainability.

Stable Returns on Invested Capital

ROIC has remained in a narrow 3.0-3.8% band over the past ten quarters, with ROE ranging from 4.0% to 5.9%. As reported in financial statements, these returns are modest but stable, reflecting a capital-intensive model with heavy PPE investment.

The stability of ROIC around 3.5% suggests that EHC is generating consistent returns on its growing asset base, but the absolute level is low compared to the cost of capital, implying that value creation is modest. The improvement in ROE from 4.1% in Q3 2024 to 5.9% in Q1 2026 is driven by margin expansion and a declining equity base due to buybacks, but the trend is not yet a clear compounding story. Investors should monitor whether de novo hospital investments can lift ROIC above the current plateau.

Working Capital Efficiency Stable

Asset turnover has been flat at 0.22x over the past ten quarters, while DSO improved from 43 days in Q1 2024 to 39 days in Q2 2026. Based on reported figures, the cash conversion cycle is minimal, indicating efficient working capital management.

The stable asset turnover of 0.22x reflects the capital-intensive nature of hospital operations, where revenue per dollar of assets is inherently low. The improvement in DSO from 43 to 39 days suggests better receivables collection, likely due to payer mix shifts toward Medicare Advantage. The absence of inventory data and minimal DPO fluctuations indicate that working capital is not a major source of cash flow variability, consistent with the prior finding that working capital changes are less than 1% of revenue.

Deleveraging Trend Improves Coverage

Debt-to-equity improved from 1.21 in Q1 2024 to 0.82 in Q2 2026, while interest coverage rose from 6.07x to 8.98x. According to recent SEC filings, total debt remained stable near $2.8B, indicating deleveraging through equity growth.

The consistent decline in D/E from 1.21 to 0.82 over ten quarters is a positive sign, as it suggests the company is growing equity faster than debt, partly due to retained earnings. Interest coverage improved from 6.07x to 8.98x, providing a comfortable cushion for debt service. However, the reported D/E of 0.82 appears unusually low for a capital-intensive hospital operator, and the prior balance sheet analysis flagged potential off-balance-sheet obligations, so investors should verify the completeness of the debt figures.

Thin Cash Buffer but Improving Liquidity

Current ratio improved from 1.05 in Q1 2024 to 1.19 in Q2 2026, but cash remains low at $107.7M, representing only 1.4% of total assets. As reported in financial statements, this suggests a tight liquidity position relative to the company's scale.

The current ratio above 1.0 indicates that current assets exceed current liabilities, but the thin cash balance of $107.7M against a $7.5B asset base leaves little room for unexpected cash needs. The improvement in the current ratio from 1.05 to 1.19 is driven by higher receivables and other current assets, not cash accumulation. Under a severe stress scenario, such as a sudden reimbursement cut, the company would likely rely on its revolving credit facility, given the minimal cash buffer.

Misapplied Debt-to-Equity Ratio

The reported D/E of 0.82 is likely understated for a capital-intensive hospital operator, as it may exclude operating lease liabilities and other off-balance-sheet obligations. Based on reported figures, this ratio obscures true leverage and should be adjusted for leases.

The D/E ratio is commonly used to assess leverage, but for EHC, the reported figure of 0.82 appears inconsistent with the sector norm and the company's heavy PPE investment. The prior balance sheet analysis noted that PPE is 60% of total assets, and the company likely has significant operating leases for facilities that are not captured in the reported debt. A more appropriate measure would be to capitalize operating leases and include them in debt, which would likely raise the effective D/E and lower interest coverage. Investors should adjust for lease liabilities to get a true picture of financial risk.

Download Financial Ratios Data

Includes 30+ ratios · 30 years · Updated daily

Consensus & Technical Research Suite
Open EHC Terminal

EHC Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

EHC — Frequently Asked Questions

Quick answers to the most common questions about buying EHC stock.

What is Encompass Health Corporation's P/E ratio?

Encompass Health Corporation's current P/E ratio is 22.0x. The historical average is 19.1x. This places it at the 78th percentile of its historical range.

What is Encompass Health Corporation's EV/EBITDA?

Encompass Health Corporation's current EV/EBITDA is 10.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 11.8x.

What is Encompass Health Corporation's ROE?

Encompass Health Corporation's return on equity (ROE) is 18.5%. The historical average is 23.7%.

Is EHC stock overvalued?

Based on historical data, Encompass Health Corporation is trading at a P/E of 22.0x. This is at the 78th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What is Encompass Health Corporation's dividend yield?

Encompass Health Corporation's current dividend yield is 0.57% with a payout ratio of 12.6%.

What are Encompass Health Corporation's profit margins?

Encompass Health Corporation has 95.7% gross margin and 17.7% operating margin. Operating margin between 10-20% is typical for established companies.

How much debt does Encompass Health Corporation have?

Encompass Health Corporation's Debt/EBITDA ratio is 2.0x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.